Compliance in epilepsy
著者
書誌事項
Compliance in epilepsy
（Epilepsy research. Supplement, Supplement,
Elsevier , Sole distributors for the USA and Canada, Elsevier Science Pub. Co., c1988
大学図書館所蔵 件 / 全3件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Based on the First International Compliance in Epilepsy Workshop held in Salzburg, Austria on Sept. 3-5, 1987
内容説明・目次
内容説明
Compliance is usually seen as the extent to which the patient's behaviour coincides with medical or health advice. Compliance carries succinctly different connotations for those who participate in its process. For the patient it may mean taking a drug regularly despite a number of grave reservations, or may mean depleting one's life style from pleasant and rewarding activities. Most of all, compliance requires giving up or curtailing the extent of individual freedom. It is generally accepted that about one-third to one-half of the people who are on chronic medication regimes use their medication in ways that differ from the clinical prescription. For evaluation of the various degrees of compliance it would be helpful to learn more about the risk - benefit ratio of less than complete compliance. All these important points, and more, are presented and reviewed in Compliance in Epilepsy.
目次
Introduction. Compliance in Epilepsy (D. Schmidt and I.E. Leppik). The Scope of the Problem. Chapter 1. Denial, delay and disappointment: discovering and overcoming the causes of drug errors and missed appointments (L.W. Green and D. Simons-Morton). Chapter 2. Compliance in children and adults: review of studies (J.T. Shope). The Patient's Perspective. Chapter 3. Compliance - a joint effort of the patient and his doctor (M. Feuerstein, V. Lieb-Juckstock, H. Schnaus, E. Springmann, B. Weber and M. Wunderlich). Chapter 4. Doctors' orders and patients' self-interest: two views of medication usage? (J. Trostle). Chapter 5. Psychological aspects of non-compliance (P.J. Thompson). Measurement of Compliance. Chapter 6. Measurement of complicance through patient interviews (R. Thorbecke). Chapter 7. Variability of phenytoin, carbamazepine and valproate concentrations in a clinic population (I.E. Leppik). Chapter 8. Compliant populations: variability in serum concentrations (N.M. Graves, G.B. Holmes and I.E. Leppik). Chapter 9. Pharmacokinetics and medication compliance (J. Cloyd). Relevance of Compliance. Chapter 10. Aspects of compliance: taking drugs and keeping clinic appointments (R.H. Mattson, J.A. Cramer, J.F. Collins and the VA Epilepsy Cooperative Study Group). Chapter 11. Patients with epilepsy who discontinue treatment (R. Thorbecke). Chapter 12. Compliance in clinical trials: impact on design, analyses and interpretation (G.W. Pledger). Chapter 13. Determinants of compliance in epileptic patients (P. Loiseau and C. Marchal). Chapter 14. Relevance of poor compliance for seizure control (D. Schmidt, R. Reininghaus and R. Winkel). Chapter 15. Compliance in epileptic children in Japan (T. Kurokawa, T. Minami, I. Kitamoto, Y. Mizuno, Y. Maeda and S. Takaki). Chapter 16. Self-induction of seizures: the ultimate non-compliance (C.D. Binnie). Chapter 17. Psychogenic seizures: a complication of compliance in epileptic patients. Two illustrative case reports (T. Damaschke). Strategies to Improve Compliance. Chapter 18. Strategies to enhance adherence to a medical regimen (J.A. Cramer and M.L. Russell). Consensus Statement. Chapter 19. Consensus statement on compliance in epilepsy (I.E. Leppik and D. Schmidt).
「Nielsen BookData」 より